Healthcare Industry News:  TAXUS Express2 

Devices Interventional Cardiology Regulatory

 News Release - April 3, 2007

Boston Scientific Announces Japanese Approval for the TAXUS(R) Express2(TM) Stent System

NATICK, Mass., April 3 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS® Express2(TM) paclitaxel-eluting coronary stent system in Japan. The Company plans to launch the product after reimbursement approval is granted.

"The approval of the TAXUS Express2 stent is an important event for the treatment of cardiovascular disease in Japan," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are pleased to provide Japanese physicians with this proven technology, which will help improve the quality of life for so many patients."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


Source: Boston Scientific

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.